Assessing Physical and Cognitive Function in Individuals With Head and Neck Cancer

Abstract

BackgroundHead and neck cancer (HNC) and associated treatments have significant long-term and late adverse effects that can impair function. Therefore, there is a need for reliable common metrics to assess function in HNC that limit participant burden and are cost-effective and easy to use in clinical settings.ObjectiveThe aim of this study was to assess the feasibility of using the Fitbit Zip, NIH Toolbox, and REDCap electronic data collection tool to measure function and symptoms in individuals with HNC and to explore preliminary findings.MethodsA prospective descriptive design with a total of 16 participants was used to assess function and symptoms pretreatment to 3 months post treatment initiation.ResultsThe enrollment rate was 49%, the retention rate was 81%, and the Fitbit Zip adherence rate was 86%. Exploratory analyses suggested a possible decline in physical activity and worsening symptom burden alongside improved attention and cognitive flexibility abilities (P ≤ .05). There were no differences in strength, functional mobility, information processing, or perceived attentional function.ConclusionThe results of this study suggest that use of the Fitbit Zip, NIH Toolbox, and REDCap data collection tool in HNC is feasible. Exploratory analyses suggest that the Fitbit Zip may be a sensitive measure of physical activity in HNC.Implications for PracticeThis study provides preliminary evidence for metrics that could be used in the clinical settings to assess function and symptom distress in HNC. Integration of these measures, upon further validation, could help providers better identify patients in need of intervention.

Investigating sarcopenia, physical activity, and inflammation biomarkers in newly diagnosed oral cancer patients undergoing curative treatment: A prospective longitudinal study

“…Decline in PA levels in the participants may be a treatment-related symptom or a part of a cluster of inflammation-associated conditions. In a previous prospective descriptive study, 41 daily step count was used as a measure for evaluating PA levels in newly diagnosed HNC patients undergoing curative (chemo)radiotherapy. The study found that in most participants, the nadir in step count was observed during or shortly after treatment, suggesting that changes in PA levels were likely related to treatment.…”